S1PR1 and atopic eczema: Although further study is needed to delineate the detailed signal pathways underlying the mode of action of KRO-105714, our results strongly suggest that KRO-105714, a novel SPC and S1P1 antagonist, is a potential therapeutic reagent with low toxicity for atopic dermatitis.